
RoslinCT and BOOST Pharma partner to advance infant cell therapy for osteogenesis imperfecta
RoslinCT and BOOST Pharma Forge Strategic Partnership to Advance Groundbreaking Cell Therapy for Infants with Osteogenesis Imperfecta In a major step forward for pediatric rare disease therapy, RoslinCT, a globally…












